北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 血液科  > 期刊论文
学科主题: 临床医学
题名:
A multicenter, open-label study of posaconazole oral suspension in the treatment of invasive fungal infections in patients refractory to or intolerant of first-line therapy
作者: Huang, Xiaojun1; Wang, Fengrong1; Chen, Yuhong1; Liu, Ting2; Wang, Jianxiang3,4,5; Hu, Jianda6; Jie, Jin7; Chen, Fangping8; Wang, Shujie9; Shen, Zhixiang10; Yu, Li11; Yu, Kang12; Liang, Yingmin13
关键词: efficacy ; invasive fungal infection ; posaconazole
刊名: FUTURE MICROBIOLOGY
发表日期: 2012-02-01
DOI: 10.2217/FMB.11.158
卷: 7, 期:2, 页:201-209
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Microbiology
研究领域[WOS]: Microbiology
关键词[WOS]: AMPHOTERICIN-B ; ANTIFUNGAL AGENTS ; ASPERGILLOSIS ; RESISTANCE ; SPECTRUM
英文摘要:

Aim: Invasive fungal infections pose a severe health threat to patients. Despite recent advances in drug development, treatment of recurrent fungal infections remains difficult. Posaconazole is a broad-spectrum triazole antifungal drug available for oral administration. Although initial studies have described its use in treating various fungal infections, its efficacy and safety in patients with invasive fungal infections remains to be further confirmed. Materials & Methods: In this study, we performed a multicenter, open-label clinical trial of posaconazole oral suspension in the treatment of 63 patients with invasive fungal infections who were refractory to or intolerant of first-line therapy. Results: Our result showed that 64.4% of patients had a clinical response after posaconazole treatment, with 52.9% showing eradication of the fungal infection. The treatment caused some adverse effects of mild or moderate severity that were of short duration. Conclusion: The results of this trial indicate that posaconazole can be used in invasive fungal infections as an alternative or salvage therapy.

语种: 英语
项目资助者: Merck &amp ; Co., Inc., Whitehouse Station, NJ, USA
WOS记录号: WOS:000300277900010
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/63990
Appears in Collections:北京大学第二临床医学院_血液科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Inst Hematol, Peoples Hosp, Beijing 100871, Peoples R China
2.Sichuan Univ, Huaxi Hosp, Chengdu 610064, Peoples R China
3.Chinese Acad Med Sci, Inst Hematol, Tianjin, Peoples R China
4.Chinese Acad Med Sci, Blood Dis Hosp, Tianjin, Peoples R China
5.Peking Union Med Coll, Tianjin, Peoples R China
6.Fujian Med Univ, Union Hosp, Fuzhou, Fujian, Peoples R China
7.Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China
8.Cent S Univ, Xiangya Hosp, Changsha, Hunan, Peoples R China
9.Wenzhou Med Coll, Wenzhou, Zhejiang, Peoples R China
10.Beijing Union Med Coll Hosp, Beijing 100730, Peoples R China
11.Shanghai Jiao Tong Univ, Rui Jin Hosp, Sch Med, Shanghai 200030, Peoples R China
12.Chinese Peoples Liberat Army, Gen Hosp, Beijing, Peoples R China
13.Fourth Mil Med Univ Xian, Tangdu Hosp, Xian, Peoples R China

Recommended Citation:
Huang, Xiaojun,Wang, Fengrong,Chen, Yuhong,et al. A multicenter, open-label study of posaconazole oral suspension in the treatment of invasive fungal infections in patients refractory to or intolerant of first-line therapy[J]. FUTURE MICROBIOLOGY,2012,7(2):201-209.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Huang, Xiaojun]'s Articles
[Wang, Fengrong]'s Articles
[Chen, Yuhong]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Huang, Xiaojun]‘s Articles
[Wang, Fengrong]‘s Articles
[Chen, Yuhong]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace